Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero- unsatisfactory cure rates even in special sub- geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa- effective supportive care show some increase tients other cases prove to be highly resis- in the initial response rates and certain im- tant. The curability is superior in acute provements in the long-term results, ...
Read More
Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero- unsatisfactory cure rates even in special sub- geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa- effective supportive care show some increase tients other cases prove to be highly resis- in the initial response rates and certain im- tant. The curability is superior in acute provements in the long-term results, no ben- lymphoblastic (ALL) than in acute myeloid eficial effect on the relapse rate during the (AML) leukemia and - within both type- first 1 Y2 years emerged from any of these higher in children as compared to adults. regimens. Thus, high chances for cure are The two age groups and cell types can be presently restricted to children with ALL further subdivided into prognostic groups and to lesser proportions children with by special diagnostic features. Thus, in AML and adults with ALL and AML.
Read Less
Add this copy of Acute Leukemias II: Prognostic Factors and Treatment to cart. $112.32, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 1990 by Springer.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Print on demand Trade paperback (US). Glued binding. 776 p. Contains: Illustrations, black & white, Tables, black & white. Haematology and Blood Transfusion Hämatologie Und Bluttransf, 33.
